


























Abstract. Background: Occupational exposure and life style
preferences, such as smoking are the main known environmental
susceptibility factors for bladder cancer. A growing list of
chemicals has been shown to induce oxidative DNA damage.
Base excision repair (BER) genes (X-ray repair cross
complementing 1, XRCC1 and human 8-oxoguanine DNA
glycosylase 1, OGG1) may play a key role in maintaining genome
integrity and preventing cancer development. Materials and
Methods: We tested whether polymorphisms in XRCC1 and
OGG1 are associated with bladder cancer risk by using
Polymerase Chain Reaction-Restriction Fragment Length
Polymorphism (PCR-RFLP) assay. In addition, the possible
modifying affect of cigarette smoking was evaluated. Results: No
studies, to date, have examined the association between genetic
polymorphisms in DNA repair genes and bladder cancer
susceptibility, in the Turkish population. We found the OGG1
Cys326Cys genotype to be more frequent among bladder cancer
patients (odds ratio (OR): 2.41 (95% CI, 1.36-4.25)). However,
in the case of XRCC1, there was no significant difference in
susceptibility to bladder cancer development between patients
with the Arg399 and these with the Gln399 allele (OR: 0.72
(95% CI, 0.41-1.26)). Conclusion: Our data showed that OGG1
genetic polymorphisms might be useful as prognostic genetic
markers for bladder cancer in the clinical setting.
Bladder cancer is the sixth most common cancer in the United
States, with 53200 incident cases estimated for the year 2000
(1). In the Turkish population, it is the third most common
cancer in men and the eighth in women (2). Oxidative DNA
damage induced by reactive oxygen species (ROS) is thought
to be involved in the processes of carcinogenesis and aging
(3). In the case of cancer, oxidative damage to DNA is
associated with mutations that activate oncogenes or
inactivate tumor suppressor genes (4). Cigarette smoking is
the dominant risk factor for several epithelial cancers,
including the lung, bladder, oral cavity, pharynx and larynx (5).
Smoking constitutes the single most important cause of
bladder cancer, with cigarette smokers having 2- to 4-fold
higher incidences than nonsmokers, and causes direct and
indirect damage to DNA (6, 7). The repair of DNA damage is
under genetic control. DNA repair genes may play a key role
in maintaining genome integrity and preventing cancer
development. At least 135 single nucleotide polymorphism
(SNPs) in 17 DNA repair and repair related genes have been
identified, including genes for nucleotide excision repair
(NER), base excision repair (BER), homologous
recombination repair (HRR) for double-strand breaks, and
cell-cycle check point. Amino acid substitution variants of
DNA repair genes could alter either DNA repair capacity or
fidelity, and may contribute to cancer susceptibility (8).
Polymorphisms in DNA repair genes resulting in variation of
DNA repair efficiency may therefore be associated with
bladder cancer susceptibility (9). Among DNA damage
induced by ROS, 8-hydroxyguanine (8-OHG) is highly
mutagenic, yielding GC to TA transversions upon its
replication by DNA polymerases. The primary pathway for the
repair of 8-OHG is short patch BER (10). X-ray repair cross
complementing 1 (XRCC1) protein probably participates in
this pathway (11). Although the precise function of XRCC1
is not known, it may have an important role in DNA single-
strand breaks (SSBR) and BER (12). XRCC1 is an abundant
nuclear zinc finger protein and part of a DNA binding protein
complex. Although the XRCC1 protein has no enzymatic
activity itself, it interacts with key enzymes involved in BER
including poly (ADP-ribose) polymerase, DNA polymerase ‚,
DNA ligase III, and AP endonuclease (APE1), a rate-limiting
enzyme in BER. Therefore, polymorphisms causing amino
acid substitutions may impair the interaction of XRCC1 with
other enzymatic proteins, and alter the BER activity (13).
There are three polymorphisms in the XRCC1 gene, which
result in amino acid changes at evolutionarily conserved
regions. Another key component of BER pathway is human
8-oxoguanine DNA glycosylase 1 (OGG1) which catalyzes the
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removal of 8-OHdG. Studies on the genetic structure of
OGG1 revealed the presence of several polymorphisms within
this locus (14). Among them, OGG1 Ser326Cys polymorphism
is of particular interest, since it may play a major role in
different kinds of cancers. The amino acid substitution from
serine to cysteine in codon 326 is the result of a C/G
substitution at position 1245 in the 1-specific exon 7 of OGG1
(15). Several studies have suggested that the Cys326 variant is
associated with increased risk for lung, bladder, and stomach
cancer (13, 16). In this study, we investigated the potential
contribution of XRCC1 (Arg399Gln) and OGG1 (Ser326Cys)
polymorphisms to bladder cancer, in a case/control study in
the Turkish population. 
Materials and Methods
Five milliliters of peripheral blood was collected from 75 bladder
cancer patients and 100 age-matched controls in EDTA containers via
venipuncture. A detailed description of the patients has been published
(17). The mean age of the bladder cancer patients was 59.87 years, with
a standard deviation and range of 12.54 and 25-87 years, respectively;
the mean age of the control group was 59.33 years, with a standard
deviation and range of 13.58 and 23-79 years, respectively. The control
subjects had no previous or present history of malignancies and were
excluded from the study if there was any evidence of major organ
disease, family history of cancer and or if taking any medication. The
patients were diagnosed at the Hacettepe University Medical School
and Ankara Numune Hospital, Turkey. Informed consent was obtained
from all study participants. In addition to clinical information and
tumor histopathology, subjects completed a questionnaire. Smoking
status information was based on self report, and only 48 patients gave
information on smoking preferences. Genomic DNA was extracted
from whole blood using a sodium perchlorate / chloroform extraction
method, as described elsewhere (18).
All patients and control subjects were screened for polymorphic
sites both OGG1 and XRCC1 genes. A simple PCR-RFLP method
was used to identify the Ser326Cys variant described by Karahalil and
Kocabas (18), because the C to G transversion creates a new Fnu4HI
restriction site. Briefly, a 207 bp fragment was amplified by PCR in a
30 Ìl reaction volume that contained 100 ng genomic DNA, 0.2 mM
of dNTP, 15 mM MgCl2, 18 pmol of the OGG1 sense (5’-ACT
GTCACTAGTCTCACCAG-3’) and antisense (5’-TGAATTC
GGAAGGTGCTTGGGGAAT-3’) primers and 3 units of Taq DNA
polymerase (Fermentas, Vilius, Lithuania). Cycling conditions were
as follows: initial denaturation at 94ÆC for 2 min, then amplification
was done using 33 cycles of denaturation at 94ÆC for 15 sec,
annealing at 60ÆC for 30 sec and extension at 72ÆC for 35 sec,
followed by final extension at 72ÆC for 3 min. Five Ìl of each PCR
sample was digested with 6 units of Fnu4HI (Fermentas, Vilius,
Lithuania) at 37ÆC overnight and resolved on 6% polyacrylamide gels
to detect 107 bp and 100 bp fragments for the 326Cys allele in RFLP
patterns. The digested products were photographed using a Genecam
System (Spectronics GL-2000, MA, USA).
The XRCC1 alleles were detected using PCR-RFLP which was a
modification of the method described by Sturgis et al. (1999) (19).
The sequences of the PCR primers were 5’-CAGTGGTGCTA
ACCTAATC-3’ (forward) and 5’-AGTAGTCTGCTGGCTCTGG-3’
(reverse), to generate an 871 bp product. A 30 ml PCR reaction was
performed using approx 0.2 to 0.5 Ìg genomic DNA, 0.25 mM each
primer, 200 ÌM of each dNTP, 1.5 U Taq polymerase (Promega,
Madison, WI, USA) in the 1xPCR buffer supplied by the
manufacturer (50 mM KCl, 10 mM Tris-HCl, pH 9,0. 1% TritonX-
100). After an initial melting step at 95ÆC for 5 min, amplification
was carried out for 35 cycles by denaturing at 95ÆC for 30 min,
annealing at 58ÆC for 45 min, extending at 72ÆC for 45 min, and a
final extention at 72ÆC for 10 min for 1 cycle. The PCR products
were digested with Nci I restriction enzyme (New England Biolabs,
UK) to distinguish the point mutation at 28152 of cDNA sequence
at exon 10. The digestion of 6 Ìl of PCR products was carried out
using 8U Nci I and the 1xNEB4 buffer at 37ÆC overnight. The wild
allele (i.e. 28152 G) has an Nci I restriction enzyme site and gives rise
to two fragments of 461 and 182 bp. The mutant allele (i.e. 28152 A)
loses the Nci I site resulting in a single 593 bp fragment. To analyze
the restriction fragments, 3% 1:1 ratio of Agarose: Gamma
microspore gel (Prone, Burgos, Spain) was used. The digested
products were photographed using Genecam system (Spectronics
GL-2000, MA, USA).
Statistical analysis. We used SPSS for statistical analysis including
Fischer’s exact test. We used standard methods for 2x2 contingency
tables, including Fisher’s exact test, as appropriate, to analyze
categorical variables without adjustment for covariates. The strengths
of associations between bladder cancer and the OGG1 and XRCC1
polymorphisms were measured as odds ratios (Ors). We classified
XRCC1 and OGG1 genotypes as: homozygous wild-type (Arg399Arg),
(Ser326Ser); heterozygous (Arg399Gln), (Ser326Cys); homozygous
variant (Gln399Gln), (Cys326Cys). The XRCC1 (Arg399Arg) and
OGG1 (Ser399Ser) were designated as reference genotypes, since
they are thought to have the highest enzymatic activity. We tested the
genotype-genotype interaction, using Fisher’s exact test. 
Results
The frequency distributions of both genotypes and alleles for
XRCC1 and OGG1 are shown in Tables I and II. In the case
of XRCC1 Arg399Gln polymorphism, there was no significant
difference in the frequency of the 399Gln allele, between
patients and controls [OR: 0.72 (95% CI, 0.41-1.26), p=0.16].
The role of the Gln399Gln XRCC1 in bladder cancer
susceptibility is unclear, because of inconsistent findings
reported in the literature. Whereas some studies showed that
the mutant allele had a protective effect in bladder cancer
development, others found an increased risk (20). Neither a
protective effect nor an increased risk due to the mutant allele
was observed for bladder cancer in the present study (Table
I). In the case of OGG1 Ser326Cys polymorphism, the mutant
allele frequency among patients and controls was 0.36 and
0.28, respectively (Table II). We found that carriers of the
326Cys allele were more frequent among bladder cancer
patients with an OR of 2.41 (95% CI, 1.36-4.25, p=0.002).
Stratification of the data according to smoking status did not
change the results for either XRCC1 Arg399Gln or OGG1
Ser326Cys polymorphisms (data not shown). Although an
inverse association between XRCC1 Arg399Gly and bladder
cancer was observed (OR=0.28; 95% CI=0.08-1.02, p=0.045)
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amongst those who never smoke (Table I), this finding needs
to be tested with a larger study population. 
Table III presents results of the analysis that evaluated the
joint effects of polymorphism at OGG1 codon 326 and
XRCC1 codon 399. We considered as the reference group for
this analysis those carriers of the genotypes found to be at
lowest risk of disease (i.e., Ser326Ser for OGG1 and Arg399Arg
for XRCC1). As shown in Table III, there was no increased
risk in individuals who carried only one of the two
polymorphisms associated with bladder cancer (i.e., OGG1
Ser326Cys-Cys326Cys or XRCC1 Arg399Arg (OR: 0.86; %95
CI, 0.35-2.13)). 
Discussion
Polymorphism in DNA repair genes resulting in variation of
DNA repair efficiency may be associated with bladder cancer
risk (9). The human genome encodes information to protect
its own integrity (21). DNA repair enzymes continuously
monitor chromosomes to correct damaged nucleotide
residues, generated by exposure to carcinogens and cytotoxic
Karahalil et al: XRCC1 and OGG1 Genes and Bladder Cancer
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Table I. XRCC1 genetic polymorphism and bladder cancer susceptibility.
XRCC1 Compared groups Odds ratio p-value
XRCC1 genotype frequency allele frequency for XRCC1 (95% CI)a
Arg399Arg Arg399Gln Gln399Gln Arg399 Gln399
Patients (n=100)* 49 38 13 68 32
Patients (n=48)# 43.7 41.6 14.6 64.5 35 Patients* versus Controls 0.72 (0.41-1.26) 0.16
S (n=35) 25 37.5 10.5 43.7 29.0 Patients# versus Controls 0.89 (0.45-1.79) 0.44
NS (n=13) 18.7 4.1 4.1 20.8 6.0 Patients versus Control 1.52 (0.60-3.81) 0.26
Patients versus Control 0.28 (0.08-1.02) 0.04b
Controls (n=100) 41 42 17 62 38
S (n=43) 19 16 8 27 16
NS (n=57) 22 26 9 35 22
aOdds ratios with 95% confidence intervals (95% CI) and p-values were calculated for wild/wild genotype versus wild/mutant and mutant/mutant
genotypes; bstatistically significant. S, smokers; NS, non-smokers. *No information available about smoking habits; #information available about
smoking habits.
Table III. Gene-gene interaction and bladder cancer susceptibility.
Gene-gene grouping Patients Controls OR (% CI)
OGG1 XRCC1 
Ser326Ser Arg399Arg 23 24 1.0
Ser326Cys+ Arg399Arg 14 17 0.86 (0.35-2.13)
Cys326Cys
Ser326Cys+ Arg399Gln+ 33 21 1.64 (0.74-3.61)
Cys326Cys Gln399Gln
Ser326Ser Arg399Gln+ 17 38 0.47 (0.21-1.04)
Gln399Gln
OR: Odds ratio determined using Fischer’s exact test.
Table II. OGG1 Ser326Cys genetic polymorphism and bladder cancer susceptibility.
OGG1 Compared groups Odds ratio p-value
OGG1 genotype frequency allele frequency for OGG1 (95% CI)a
Ser326Ser Ser326Cys Cys326Cys Ser326 Cys326
Patients (n=99)* 40 47 12 64 36
Patients (n=47)# 44.7 42.5 12.8 65.9 34 Patients* versus Controls 2.41 (1.36-4.25) 0.002b
S (n=34) 29.8 34.0 8.5 46.8 25.5 Patients# versus Controls 2.02 (1.00-4.08) 0.036c
NS (n=13) 14.9 8.5 4.3 19.1 8.5 Patients versus control 1.13 (0.45-2.81) 0.49
Patients versus control 1.71 (0.51-5.82) 0.29
Controls (n=100) 62 20 18 72 28
S (n=43) 27 9 7 32 11
NS (n=57) 38 9 10 43 14
aOdds ratios with 95% confidence intervals (95% CI) and p-values were calculated for wild/wild genotype versus wild/mutant and mutant/mutant
genotypes; b,cstatistically significant. S, smokers; NS, non-smokers. *No information available about smoking habits; #information available about
smoking habits.
compounds (22). Several studies have screened DNA repair
genes for the presence of polymorphic alleles (9, 23). It is
possible that the inherited polymorphism of the recombinant
repair pathway may affect the risk of bladder cancer. In our
previous study, the allelic frequencies of the XRCC1 gene in
166 of the healthy Turkish population were 0.60 for the
399Arg polymorphism and 0.40 for the 399Gln polymorphism
and were similar to those for the Caucasian population (21).
Kim et al. carried out a study to determine whether
polymorphism of tumor necrosis factor-alpha (TNF-alpha),
vascular endothelial growth factor (VEGF), OGG1,
glutathione S-transferase-Ì (GSTM1), and glutathione S-
transferase-Ê (GSTT1) are risk factors for bladder cancer
amongst Koreans (22). They showed that GSTM1-negative,
GSTT1-positive, and OGG1 Ser326Ser and Ser326Cys
genotypes are risk factors for bladder cancer. Our result for
OGG1 polymorphism in bladder cancer patients is similar to
their findings. Stern et al. tested whether XRCC1 polymorphism
was associated with bladder cancer risk and also examined
gene-environment interactions (20). They found no evidence of
an association between the codon 280 variant and bladder
cancer risk. On the other hand, they found evidence of a
protective effect for patients that carried at least one copy of
the codon 194 and 399 variant allele.
In conclusion, the role of Gln399Gln XRCC1 is unclear,
because of the contradictory data reported, regarding its
protective effect and its association with an increased risk.
Our data did not suggest a protective effect. On the other
hand OGG1 Cys326Cys does appear to be a risk factor for
bladder cancer. 
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